Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Galiximab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Galiximab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Galiximab. |
| Estrone | Estrone may increase the thrombogenic activities of Galiximab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Galiximab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Galiximab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Galiximab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Galiximab. |
| Estriol | Estriol may increase the thrombogenic activities of Galiximab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Galiximab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Galiximab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Galiximab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Galiximab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Galiximab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Galiximab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Galiximab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Galiximab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Galiximab. |
| Equol | Equol may increase the thrombogenic activities of Galiximab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Galiximab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Galiximab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Galiximab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Galiximab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Galiximab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Galiximab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Galiximab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Galiximab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Galiximab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Galiximab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Galiximab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Galiximab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Galiximab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Galiximab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Galiximab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Galiximab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Galiximab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Galiximab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Galiximab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Galiximab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Galiximab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Galiximab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Galiximab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Galiximab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Galiximab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Galiximab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Galiximab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Galiximab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Galiximab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Galiximab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Galiximab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Galiximab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Galiximab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Galiximab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Galiximab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Galiximab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Galiximab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Galiximab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Galiximab is combined with Pexelizumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Galiximab is combined with Afelimomab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Galiximab is combined with Epratuzumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Galiximab is combined with Bectumomab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Galiximab is combined with Oregovomab. |
| IGN311 | The risk or severity of adverse effects can be increased when Galiximab is combined with IGN311. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Galiximab is combined with Adecatumumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Galiximab is combined with Labetuzumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Galiximab is combined with Matuzumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Galiximab is combined with Fontolizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Bavituximab. |
| CR002 | The risk or severity of adverse effects can be increased when Galiximab is combined with CR002. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Galiximab is combined with Rozrolimupab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Girentuximab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Obiltoxaximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when Galiximab is combined with XTL-001. |
| NAV 1800 | The risk or severity of adverse effects can be increased when Galiximab is combined with NAV 1800. |
| Briakinumab | The risk or severity of adverse effects can be increased when Galiximab is combined with Briakinumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Galiximab is combined with Otelixizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when Galiximab is combined with AMG 108. |
| Iratumumab | The risk or severity of adverse effects can be increased when Galiximab is combined with Iratumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Galiximab is combined with Enokizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Galiximab is combined with Ramucirumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Galiximab is combined with Farletuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Galiximab is combined with Veltuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Galiximab is combined with Ustekinumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Galiximab is combined with Trastuzumab emtansine. |
| PRO-542 | The risk or severity of adverse effects can be increased when Galiximab is combined with PRO-542. |
| TNX-901 | The risk or severity of adverse effects can be increased when Galiximab is combined with TNX-901. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Galiximab is combined with Inotuzumab ozogamicin. |
| RI 624 | The risk or severity of adverse effects can be increased when Galiximab is combined with RI 624. |
| Stamulumab | The risk or severity of adverse effects can be increased when Galiximab is combined with MYO-029. |
| CT-011 | The risk or severity of adverse effects can be increased when Galiximab is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when Galiximab is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Galiximab is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Galiximab is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when Galiximab is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when Galiximab is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Galiximab is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when Galiximab is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when Galiximab is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Galiximab is combined with Canakinumab. |